20 June 2014BiotechFranz-Josef Zimmer and Markus Grammel

Tough times continue for stem cell patents

Two decisions handed down by a Technical Board of Appeal of the European Patent Office (EPO)—T 1836/10 in April 2013 and T 2221/10 in February 2014—seem to cement the restrictive approach that has taken hold at the EPO with regard to the patenting of human embryonic stem cells (hESCs).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

Biotech

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

1 September 2026 Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product.

Biotech

Tempus AI bid to derail DNA patent case hits snag

31 August 2026 Efforts to shut down an eight-patent dispute over cancer-detection technology have run into a hurdle in a Delaware federal court.